<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951702</url>
  </required_header>
  <id_info>
    <org_study_id>940920-2</org_study_id>
    <nct_id>NCT02951702</nct_id>
  </id_info>
  <brief_title>Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics</brief_title>
  <official_title>Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Hospital, Chesterfield, Missouri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's Hospital, Chesterfield, Missouri</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if oral vancomycin used as primary Clostridium
      difficile prophylaxis can reduce the incidence of this infection in high-risk patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clostridium difficile infection is a common healthcare-associated infection and one that is
      associated with significant morbidity as well as a risk for mortality. Current practice
      throughout the United States is targeted at infection prevention measures such as hand
      washing and isolation. Despite these measures, incidence of Clostridium difficile infections
      continue to rise as some institutions, including our own. Recently, a study published in
      Clinical Infectious Diseases found oral vancomycin for secondary prophylaxis to reduce the
      incidence of recurrence. No studies to date have evaluated primary prophylaxis with oral
      vancomycin. This will be a single center, prospective study to evaluate oral vancomycin use
      as primary Clostridium difficile prophylaxis. Patients treated by infectious disease
      physicians will be identified as &quot;high risk&quot; and after pager notification the ID physician
      will have the option to start oral vancomycin 125 mg by mouth daily if they determine it to
      be appropriate. Risk factors include age older than 65 years, taking gastric acid suppression
      medication, and receiving select broad-spectrum antibiotics. Oral vancomycin will be
      continued until de-escalation of antibiotics or hospital discharge and patients will be
      evaluated for Clostridium difficile infection development from the current hospital admission
      up to 4 weeks following antibiotic discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clostridium Difficile Infection Occurrence</measure>
    <time_frame>Within 4 weeks from the completion of antibiotic treatment</time_frame>
    <description>The incidence of clostridium difficile infection as detected for GDH/toxin positive or PCR if the GDH/toxin is equivocal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Clostridium Difficile Infection Occurence</measure>
    <time_frame>Within 4 weeks from completion of antibiotic treatment</time_frame>
    <description>This is the time from the start of antibiotics to the diagnosis of clostridium difficile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium Difficile Infection Severity</measure>
    <time_frame>Within 4 weeks from completion of antibiotic treatment</time_frame>
    <description>Severity as defined by the IDSA/SHEA guidelines (mild to moderate, defined as white-cell count less than 15,000 cells/µL or increase in serum creatinine (SCr) by &lt;1.5 times the baseline; severe, defined as white-cell count greater than 15,000 cells/µL or increase in SCr by &gt;1.5 times the baseline; and fulminant, defined as the criteria above for severe with shock, hypotension, ileus, or megacolon)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Prophylaxis</condition>
  <condition>Vancomycin</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This will be the historical arm that has not received oral vancomycin but match criteria for &quot;high risk&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin Oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Oral</intervention_name>
    <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician</description>
    <arm_group_label>Vancomycin Oral</arm_group_label>
    <other_name>Oral vancomycin; vancomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &quot;High-risk&quot; patients defined as: age older than 65, on gastric acid suppression, and
             select antibiotics

          -  Gastric acid suppression includes proton pump inhibitors and histamine-2 receptor
             antagonists

          -  Selected antibiotics include fluoroquinolone (ciprofloxacin, levofloxacin),
             clindamycin, a 3rd or 4th generation cephalosporin, a broad-spectrum aminopenicillin
             (ampicillin-sulbactam, piperacillin-tazobactam), or a carbapenem

        Exclusion Criteria:

          -  Failure to meet all three requirements for &quot;high risk&quot;

          -  Vancomycin allergy

          -  Active clostridium difficile infection prior to inclusion

          -  Prophylactic oral vancomycin prior to study inclusion (i.e. prolonged vancomycin
             taper)

          -  Receipt of medications that also treat Clostridium difficile (metronidazole,
             rifaximin, fidaxomicin)

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan E Medas, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.</citation>
    <PMID>25714160</PMID>
  </reference>
  <reference>
    <citation>O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007 Nov;28(11):1219-27. Epub 2007 Oct 3.</citation>
    <PMID>17926270</PMID>
  </reference>
  <reference>
    <citation>Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010 May;31(5):431-55. doi: 10.1086/651706.</citation>
    <PMID>20307191</PMID>
  </reference>
  <reference>
    <citation>Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S19-31. doi: 10.1086/521859. Review.</citation>
    <PMID>18177218</PMID>
  </reference>
  <reference>
    <citation>Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014 Mar 27;370(13):1198-208. doi: 10.1056/NEJMoa1306801.</citation>
    <PMID>24670166</PMID>
  </reference>
  <reference>
    <citation>Marra F, Ng K. Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. Drugs. 2015 Jul;75(10):1095-118. doi: 10.1007/s40265-015-0422-x. Review.</citation>
    <PMID>26113167</PMID>
  </reference>
  <reference>
    <citation>Van Hise NW, Bryant AM, Hennessey EK, Crannage AJ, Khoury JA, Manian FA. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents. Clin Infect Dis. 2016 Sep 1;63(5):651-3. doi: 10.1093/cid/ciw401. Epub 2016 Jun 17.</citation>
    <PMID>27318333</PMID>
  </reference>
  <reference>
    <citation>Johnson S. Editorial Commentary: Potential Risks and Rewards With Prophylaxis for Clostridium difficile Infection. Clin Infect Dis. 2016 Sep 1;63(5):654-5. doi: 10.1093/cid/ciw424. Epub 2016 Jun 28.</citation>
    <PMID>27358349</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2016</study_first_submitted>
  <study_first_submitted_qc>October 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <results_first_submitted>October 3, 2017</results_first_submitted>
  <results_first_submitted_qc>November 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 27, 2017</results_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Luke's Hospital, Chesterfield, Missouri</investigator_affiliation>
    <investigator_full_name>Ryan Medas</investigator_full_name>
    <investigator_title>PGY2 Pharmacy Internal Medicine Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>This will be the historical arm that has not received oral vancomycin but match criteria for &quot;high risk&quot;</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin</title>
          <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician
Vancomycin Oral: This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>This will be the historical arm that has not received oral vancomycin but match criteria for &quot;high risk&quot;</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin</title>
          <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician
Vancomycin Oral: This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" lower_limit="65" upper_limit="90"/>
                    <measurement group_id="B2" value="75" lower_limit="65" upper_limit="86"/>
                    <measurement group_id="B3" value="75" lower_limit="65" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clostridium Difficile Infection Occurrence</title>
        <description>The incidence of clostridium difficile infection as detected for GDH/toxin positive or PCR if the GDH/toxin is equivocal.</description>
        <time_frame>Within 4 weeks from the completion of antibiotic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This will be the historical arm that has not received oral vancomycin but match criteria for &quot;high risk&quot;</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician
Vancomycin Oral: This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician</description>
          </group>
        </group_list>
        <measure>
          <title>Clostridium Difficile Infection Occurrence</title>
          <description>The incidence of clostridium difficile infection as detected for GDH/toxin positive or PCR if the GDH/toxin is equivocal.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clostridium Difficile Infection Occurence</title>
        <description>This is the time from the start of antibiotics to the diagnosis of clostridium difficile.</description>
        <time_frame>Within 4 weeks from completion of antibiotic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This will be the historical arm that has not received oral vancomycin but match criteria for &quot;high risk&quot;</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician
Vancomycin Oral: This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clostridium Difficile Infection Occurence</title>
          <description>This is the time from the start of antibiotics to the diagnosis of clostridium difficile.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clostridium Difficile Infection Severity</title>
        <description>Severity as defined by the IDSA/SHEA guidelines (mild to moderate, defined as white-cell count less than 15,000 cells/µL or increase in serum creatinine (SCr) by &lt;1.5 times the baseline; severe, defined as white-cell count greater than 15,000 cells/µL or increase in SCr by &gt;1.5 times the baseline; and fulminant, defined as the criteria above for severe with shock, hypotension, ileus, or megacolon)</description>
        <time_frame>Within 4 weeks from completion of antibiotic treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>This will be the historical arm that has not received oral vancomycin but match criteria for &quot;high risk&quot;</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician
Vancomycin Oral: This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician</description>
          </group>
        </group_list>
        <measure>
          <title>Clostridium Difficile Infection Severity</title>
          <description>Severity as defined by the IDSA/SHEA guidelines (mild to moderate, defined as white-cell count less than 15,000 cells/µL or increase in serum creatinine (SCr) by &lt;1.5 times the baseline; severe, defined as white-cell count greater than 15,000 cells/µL or increase in SCr by &gt;1.5 times the baseline; and fulminant, defined as the criteria above for severe with shock, hypotension, ileus, or megacolon)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild-Mod</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>This will be the historical arm that has not received oral vancomycin but match criteria for &quot;high risk&quot;</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin</title>
          <description>This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician
Vancomycin Oral: This arm will receive oral vancomycin 125 mg daily if &quot;high risk&quot; and determined to be appropriate by an ID physician</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Underpowered study; primary outcome relied upon patient's developing CDI while in the hospital or follow up at the study hospital.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ryan Medas, Pharm.D.</name_or_title>
      <organization>St. Luke's Hospital</organization>
      <phone>314-205-6053</phone>
      <email>ryan.medas@stlukes-stl.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

